Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Resources Pharmaceutical Group's quarterly Total Liabilities
increased
from Dec. 2024 (HK$170,478.45 Mil) to Jun. 2025 (HK$191,082.66 Mil) but then
declined
from Jun. 2025 (HK$191,082.66 Mil) to Dec. 2025 (HK$185,986.26 Mil).
China Resources Pharmaceutical Group's annual Total Liabilities
increased
from Dec. 2023 (HK$168,218.25 Mil) to Dec. 2024 (HK$170,478.45 Mil) and
increased
from Dec. 2024 (HK$170,478.45 Mil) to Dec. 2025 (HK$185,986.26 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Pharmaceutical Group Total Liabilities Chart
China Resources Pharmaceutical Group Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of HK$185,986 Mil mean?
China Resources Pharmaceutical Group (HKSE:03320) has a Total Liabilities of HK$185,986 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for China Resources Pharmaceutical Group and its competitors.
Is China Resources Pharmaceutical Group's Total Liabilities too high?
China Resources Pharmaceutical Group's current Total Liabilities is HK$185,986 Mil. Overall, China Resources Pharmaceutical Group has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Pharmaceutical Group's Total Liabilities compare to ZTS?
China Resources Pharmaceutical Group's Total Liabilities of HK$185,986 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for China Resources Pharmaceutical Group and its competitors. China Resources Pharmaceutical Group's current Total Liabilities is HK$185,986 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group (HKSE:03320) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$6.01, compared to a current price of HK$4.85 — trading 19.3% below its estimated fair value. The current Total Liabilities is HK$185,986 Mil. China Resources Pharmaceutical Group's overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For China Resources Pharmaceutical Group (HKSE:03320), the current Total Liabilities is HK$185,986 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Pharmaceutical Group (HKSE:03320) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group stock appears to be undervalued.
The current stock price of HK$4.85 is trading 19.3% below its estimated GF Value™ of HK$6.01.
GuruFocus considers China Resources Pharmaceutical Group to be Modestly Undervalued.
Key valuation signals for HKSE:03320:
Total Liabilities: HK$185,986 Mil
GF Value™: HK$6.01 vs. price of HK$4.85 (19.3% below fair value)
No single metric tells the full story. See the HKSE:03320 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Pharmaceutical Group Ltd is principally engaged in the manufacture, distribution and retail of pharmaceutical and healthcare products. Specifically, the Group has four reportable segments as follows: Pharmaceutical manufacturing business, Pharmaceutical distribution business, Pharmaceutical retail business , and Other business operations. The company generates majority of its revenue from the Pharmaceutical distribution business.
87GF Score
Get the complete analysis for HKSE:03320
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03320 has been successfully added to your 
